Frequency Therapeutics Launches US Clinical Trials of Hearing Loss Drug; Akouos Raises $50M for Gene Therapy R&D

Biotech startup, Frequency Therapeutics, announced today that the first patients have been treated in a Phase 1/2 clinical trial to evaluate the company’s investigative compound FX-322, the company’s lead Progenitor Cell Activation (PCA) candidate for hearing restoration. The randomized, double-blind, placebo-controlled trial will assess the safety of FX-322 given by intratympanic administration in adult patients…

Read More
decibel hearing loss drug financing

Decibel Therapeutics Snags $55 Million Series C Financing for Hearing Drug Development

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, announced that it has raised $55M in a Series C financing round. According to the announcement, all the existing investors–Third rock Ventures, GV, SR One and Regeneron Pharmaceuticals–participated in the financing round and were joined alongside new investors: Foresite Capital, Bessemer Trust, Schroder Adveq, SCubed Capital, Longevity, and…

Read More
hearing loss military frequency therapeutics

Frequency Therapeutics Receives $2M Grant to Investigate Hearing Restoration for US Military

Biotech startup, Frequency Therapeutics, announced today that it has received a U.S. Department of Defense (DoD) Hearing and Balance Research Award grant. The $2 million dollar, peer-reviewed grant will be used to investigate the company’s unique Progenitor Cell Activation (PCA) approach to hearing restoration for military personnel with service-related hearing loss. Prevention of hearing loss…

Read More
acousia therapeutics hearing loss drug

Acousia Therapeutics Receives €10 Million Investment to Advance Pipeline of Preclinical Hearing Loss Drug Candidates

TÜBINGEN, GERMANY — Acousia Therapeutics, a privately held biotech firm developing novel therapies for inner ear disease and pathologies, announced this week the closing of a €10 million (approximately $11.8M USD) Series B financing round to “advance its pipeline of preclinical drug candidates into clinical stage”.  According to the announcement, the financing round was led…

Read More
hearing loss restoration rna injection

Scientists Regenerate Cochlear Hair Cells in Guinea Pigs Using RNA Injection

The cochlear hair cells of humans and other mammals–unlike some animal species (like birds for example)–cannot be restored after damage. Recent research has indicated, however, that manipulation of signaling pathways could lead to hair cell regeneration. Using a sustained-release formulation of small interfering RNAs (siRNAs) delivered via nanoparticles into the cochlea of noise-injured guinea pigs,…

Read More
hearing loss repair research

USC Scientists Develop Method to Repair Damage to Cochlea

Recent research indicates hearing loss is expected to nearly double in 40 years. This figure includes individuals who suffer from the condition of “hidden hearing loss,” which is generally defined to be damage to the inner ear that leads to difficulty hearing soft voices in the presence of background noise, but an audiogram within the…

Read More
vestibular schwannoma drug treatment

Abortion Drug Holds Promise as Treatment for Acoustic Tumors

The Boston Business Journal reported this week that Massachusetts Eye and Ear researchers plan to launch trials of a drug commonly used to induce chemical abortion, called mifepristone, to treat vestibular schwannoma. Vestibular schwannoma, a rare tumor, usually causes unilateral hearing loss and tinnitus, but can also cause dizziness and facial nerve paralysis. Because of…

Read More
dizziness drug trial

Clinical Trial For Motion Sickness Drug Now Over 50% Enrolled

WASHINGTON, DC — GT Biopharma Inc., a clinical stage biotech company, announced the Proof-of-Concept clinical trial of its novel drug treatment for motion sickness, GTP-011, is now more than 50% enrolled. According to the announcement, the trial is a single-blind, placebo-controlled, cross-over study. The study’s primary objective will be to demonstrate the efficacy of transdermal GTP-011…

Read More
auris medical tinnitus drug trial

Auris Medical Announces Disappointing Results from Tinnitus Drug Trial; Company Stock Price Plummets

ZUG, SWITZERLAND — Biopharmaceutical company Auris Medical Holdings announced disappointing results from its TACTT3 clinical trial for its promising tinnitus drug candidate, Keyzilen.  Preliminary top-line data from the trial indicate that the study did not provide a statistically significant improvement in the Tinnitus Functional Score from baseline to Day 84 in the active treated group compared…

Read More
frequency therapeutics hearing loss drug development

Frequency Therapeutics Announces Successful Completion of First-in-Human Study of FX-322, Company’s Leading Candidate for Hearing Restoration

WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced late last month the successful completion of a first-in-human study of the company’s investigative compound FX-322, the company’s lead Progenitor Cell Activation (PCA) candidate for hearing restoration. The preliminary results were recently presented at a lecture last month at the US-Japan Symposium on Drug Delivery. According to…

Read More